Racibrutinib

Racibrutinib is a targeted cancer medication used primarily to treat certain types of blood cancers, such as mantle cell lymphoma and chronic lymphocytic leukemia. It works by blocking a protein called Bruton's tyrosine kinase (BTK), which plays a key role in the survival and growth of cancerous white blood cells. By inhibiting BTK, racibrutinib helps to slow down or stop the progression of the disease. It's taken orally and is part of targeted therapy, which aims to specifically attack cancer cells while minimizing damage to healthy cells.